For Healthcare Professionals

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

clipboard-pencil

About the study

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

    EXCLUSION CRITERIA

      pin location

      Study Locations

      Enter your ZIP code/Postal code/PIN code to locate study sites near you:

      How to Apply


      Contact the study center to learn if this study is a good match for you.
      Phone iconCall 1-877-240-9479Email iconEmail Study Center

      Study’s details


      Contition

      Biliary Tract Neoplasms

      Age (in years)

      18 - 130

      Phase

      Phase 3

      Participants needed

      810

      Est. Completion Date

      Mar 2025

      Treatment type

      Interventional


      Sponsor

      AstraZeneca

      ClinicalTrials.gov identifier

      NCT03875235

      Study number

      D933AC00001

      Understanding Clinical Trials


      Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
      Vector

      Interested?

      Sign up to save your favorites, 
      receive newsletters, resources, and alerts 
      about clinical trials related to your conditions of interest.